[HTML] plos.org

[HTML][HTML] New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients

A Bellin, P Berto, S Themistoclakis, A Chandak… - PLoS …, 2019 - journals.plos.org
Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …
被引用次数：16 相关文章
[PDF] academia.edu

[PDF][PDF] New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients

A Bellin, P Berto, S Themistoclakis, A Chandak… - PLoS ONE, 2019 - academia.edu
Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …
[PDF] semanticscholar.org

[PDF][PDF] New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients

A Bellin, P Berto, S Themistoclakis… - PLoS …, 2019 - pdfs.semanticscholar.org
Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …

New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

A Bellin, P Berto, S Themistoclakis… - 2019 - cabidigitallibrary.org
Background: Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …
[HTML] nih.gov

[HTML][HTML] New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients

A Bellin, P Berto, S Themistoclakis, A Chandak… - PLoS ONE, 2019 - ncbi.nlm.nih.gov
Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …

New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

A Bellin, P Berto, S Themistoclakis, A Chandak… - PLoS …, 2019 - search.ebscohost.com
Background: Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …

New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

A Bellin, P Berto, S Themistoclakis, A Chandak… - PLoS ONE, 2019 - go.gale.com
Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …

New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

A Bellin, P Berto, S Themistoclakis, A Chandak… - Plos one, 2019 - europepmc.org
Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …

[引用][C] New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients

A Bellin, P Berto, S Themistoclakis, A Chandak… - PLoS …, 2019 - ui.adsabs.harvard.edu
New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients -
NASA/ADS Now on home page ads icon ads Enable full ADS view NASA/ADS New oral …

New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients

A Bellin, P Berto, S Themistoclakis, A Chandak… - PloS …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …